Table 1: Patient characteristics.
Values are displayed as median (interquartile range) or frequency (percentage).
| N=36 | |
|---|---|
| Age at diagnosis | 26 (22–34) |
| Laterality orchiectomy | |
| Left | 19 (53%) |
| Right | 17 (47%) |
| Teratoma in primary tumor | 15 (42%) |
| AJCC stage at presentation | |
| IB | 1 (2.8%) |
| IIA | 1 (2.8%) |
| IIC | 3 (8.3%) |
| IIIA | 3 (8.3%) |
| IIIC | 28 (78%) |
| IGCCC risk group prior to initial chemotherapy | |
| Good | 5 (14%) |
| Intermediate | 1 (2.8%) |
| Poor | 29 (81%) |
| N/A | 1 (2.8%) |
| Decrease in liver mass size post-chemo (%) (N=28) | 59 (33–79) |
| Decrease in RP mass size post-chemo (%) (N=29) | 38 (16–54) |
| Decrease in AFP post-chemo (%) (N=19) | 82 (−5–100) |
| Decrease in HCG post-chemo (%) (N=13) | 100 (100–100) |
| Second-line chemo before liver resection | 17 (47%) |
| RPLND histology | |
| Fibrosis/necrosis | 19 (53%) |
| Teratoma | 8 (22%) |
| Teratoma and viable GCT | 4 (11%) |
| Viable GCT | 5 (14%) |
| Hepatic procedure | |
| Partial hepatectomy | 15 (42%) |
| Wedge resection | 21 (58%) |
| Hepatic histology | |
| Fibrosis/necrosis | 27 (75%) |
| Teratoma | 5 (14%) |
| Viable GCT | 4 (11%) |
AJCC, American Joint Committee on Cancer; IGCCC, International Germ Cell Consensus Classification; RP, retroperitoneal; AFP, alpha fetoprotein; HCG, human chorionic gonadotropin; RPLND, retroperitoneal lymph node dissection; GCT, germ cell tumor